Royal Bank of Canada’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-3,238
| Closed | -$16K | – | 7142 |
|
|
2020
Q1 | $16K | Sell |
3,238
-2,461
| -43% | -$16K | ﹤0.01% | 5656 |
|
|
2019
Q4 | $61K | Buy |
5,699
+2,699
| +90% | +$26.8K | ﹤0.01% | 5358 |
|
|
2019
Q3 | $31K | Sell |
3,000
-47
| -2% | -$615 | ﹤0.01% | 5316 |
|
|
2019
Q2 | $47K | Buy |
3,047
+43
| +1% | +$622 | ﹤0.01% | 5318 |
|
|
2019
Q1 | $39K | Buy |
3,004
+4
| +0.1% | +$45 | ﹤0.01% | 5313 |
|
|
2018
Q4 | $29K | Sell |
3,000
-766
| -20% | -$9.93K | ﹤0.01% | 5404 |
|
|
2018
Q3 | $62K | Buy |
3,766
+622
| +20% | +$9.97K | ﹤0.01% | 5134 |
|
|
2018
Q2 | $50K | Buy |
3,144
+141
| +5% | +$2.52K | ﹤0.01% | 5158 |
|
|
2018
Q1 | $46K | Sell |
3,003
-497
| -14% | -$7.75K | ﹤0.01% | 5095 |
|
|
2017
Q4 | $55K | Sell |
3,500
-1,589
| -31% | -$21.3K | ﹤0.01% | 5136 |
|
|
2017
Q3 | $56K | Buy |
5,089
+1,985
| +64% | +$18.7K | ﹤0.01% | 5350 |
|
|
2017
Q2 | $29K | Sell |
3,104
-643
| -17% | -$5.36K | ﹤0.01% | 5391 |
|
|
2017
Q1 | $32K | Sell |
3,747
-238
| -6% | -$2.17K | ﹤0.01% | 5391 |
|
|
2016
Q4 | $43K | Buy |
+3,985
| New | +$48.2K | ﹤0.01% | 5353 |
|
|
2016
Q1 | – | Sell |
-65
| Closed | – | – | 6811 |
|
|
2015
Q4 | $0 | Sell |
65
-614
| -90% | -$4.98K | ﹤0.01% | 6945 |
|
|
2015
Q3 | $6K | Sell |
679
-213
| -24% | -$2.23K | ﹤0.01% | 6119 |
|
|
2015
Q2 | $10K | Buy |
+892
| New | +$12.4K | ﹤0.01% | 6065 |
|
|
2015
Q1 | – | Sell |
-8
| Closed | – | – | 6524 |
|
|
2014
Q4 | $0 | Buy |
+8
| New | +$115 | ﹤0.01% | 6373 |
|
|
2013
Q4 | – | Sell |
-55
| Closed | -$2K | – | 6260 |
|
|
2013
Q3 | $2K | Buy |
+55
| New | +$1.79K | ﹤0.01% | 5887 |
|
Royal Bank of Canada's STML Position: Q2 2020 in Review
Royal Bank of Canada sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 3,238 shares — an estimated $16K sold.
Royal Bank of Canada first reported a position in STML in Q3 2013 and held it in 19 quarters. The position peaked at $62K in Q3 2018. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Royal Bank of Canada reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Royal Bank of Canada sold 3,238 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $16K.
- Royal Bank of Canada first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 19 quarters.
- Royal Bank of Canada's Stemline Therapeutics, Inc. position peaked at $62K in Q3 2018.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Royal Bank of Canada's 13F filing for Q2 2020, filed 14 Aug 2020.